Success Stories

March 2019 Question of the Month

How will the HHS proposed rule changes to Medicare Part D and Medicaid drug rebate safe harbors impact pharmaceutical product net costs for PBMs?

Higher net costs after the implementation of the proposed rule: 50%

Lower net costs after the implementation of the proposed rule: 12.5%

No impact, net costs will be at the same levels as today: 37.5%

What is the likelihood brand pharmaceutical manufacturers will slow drug price increases in 2019 based on the Trump administration’s proposals?

Highly Likely: 0%

Likely: 12.5%

Unlikely: 75%

Highly Unlikely: 12.5%

Are there more challenges with the new lower priced Repatha NDC compared with the higher priced NDC?

Yes: 57.1%

No: 42.9%

Do you think brand manufacturer’s strategy to introduce a lower priced brand NDC of an existing product is going to expand in 2019?

Yes: 85.7%

No: 14.3%